Signatera is the only patient-specific, custom-built circulating tumor DNA (ctDNA) monitoring assay to support cancer treatment planning in early- and late-stage cancers.
Signatera for colorectal cancer (CRC)The personalized, molecular residual disease (MRD) assessment and surveillance monitoring tool to guide optimal treatment decision-making.
Research pipelineReview our clinical pipeline with leading institutions and biopharmaceutical partners, learn more about our registry studies, or contact us for research services.
Your health is your most important asset. You should entrust it only to the best professionals.
Treatment choices perfectly match your goals of treatment complications with early intervention.
Quality and Safety
All team members at Medical Center have been trained thoroughly to assist in any situation.